MyFinsight
Home
Blog
About
Contact
Download
Download image
Purchases of short-term
investments
-$127,343K
Net loss
$57,863K
Sale of short-term
investments
$10,075K
Purchases of property and
equipment
-$361K
Prepaid expenses and
other current assets
-$3,424K
Accounts payable
$1,268K
Other assets
-$1,256K
Non-cash loss on sale of
property and equipment
$153K
Net cash provided by
investing activities
$51,090K
Net cash used in
operating activities
$49,711K
Canceled cashflow
$86,689K
Canceled cashflow
$14,253K
Net increase in
cash, cash...
-$169,143K
Canceled cashflow
$100,801K
Proceeds from exercise of
stock options
$167K
Maturities of short-term
investments
-$86,689K
Stock-based compensation
expense
-$6,201K
Accrued expenses and
other current...
-$5,971K
Non-cash lease expense
-$879K
Operating lease
liabilities
$579K
Depreciation and
amortization
-$525K
Accounts receivable
$58K
Net (accretion) and
amortization of investments...
$40K
Net cash provided by
financing activities
-$269,944K
Canceled cashflow
$167K
something is missing
-$269,897K
Payment of deferred
offering costs
$210K
Repurchase of unvested
restricted common stock
$4K
Back
Back
Cash Flow
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)
source: myfinsight.com